What shareholders can do to beat the market with Moderna Inc. (MRNA) stock

As of close of business last night, Moderna Inc.’s stock clocked out at $151.78, up 1.46% from its previous closing price of $149.60. In other words, the price has increased by $+2.18 from its previous closing price. On the day, 2653424 shares were traded. MRNA stock price reached its highest trading level at $152.82 during the session, while it also had its lowest trading level at $147.99.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".



To gain a deeper understanding of MRNA’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.88 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.71. For the most recent quarter (mrq), Quick Ratio is recorded 2.50 and its Current Ratio is at 2.70. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, TD Cowen on March 13, 2023, Upgraded its rating to Outperform and sets its target price to $180 from $150 previously.

On March 02, 2023, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $200.

SVB Securities Downgraded its Market Perform to Underperform on February 24, 2023, whereas the target price for the stock was revised from $111 to $93.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 09 when Bancel Stephane sold 40,000 shares for $139.20 per share. The transaction valued at 5,567,859 led to the insider holds 5,411,946 shares of the business.

Bancel Stephane sold 40,000 shares of MRNA for $5,655,310 on Mar 08. The Chief Executive Officer now owns 5,411,946 shares after completing the transaction at $141.38 per share. On Mar 08, another insider, Klinger Shannon Thyme, who serves as the Chief Legal Officer of the company, sold 561 shares for $141.51 each. As a result, the insider received 79,388 and left with 5,820 shares of the company.

Valuation Measures:

As of this moment, Moderna’s Price-to-Earnings (P/E) ratio for their current fiscal year is 7.60. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.02 while its Price-to-Book (P/B) ratio in mrq is 3.08.

Stock Price History:

Over the past 52 weeks, MRNA has reached a high of $217.25, while it has fallen to a 52-week low of $115.03. The 50-Day Moving Average of the stock is 168.52, while the 200-Day Moving Average is calculated to be 157.95.

Shares Statistics:

It appears that MRNA traded 4.24M shares on average per day over the past three months and 3.45M shares per day over the past ten days. A total of 388.00M shares are outstanding, with a floating share count of 346.94M. Insiders hold about 2.40% of the company’s shares, while institutions hold 65.90% stake in the company. Shares short for MRNA as of Jan 30, 2023 were 14.13M with a Short Ratio of 15.68M, compared to 14.04M on Dec 29, 2022. Therefore, it implies a Short% of Shares Outstanding of 3.68% and a Short% of Float of 4.99%.

Earnings Estimates

As of right now, 14 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $4.68 for the current quarter, with a high estimate of $5.56 and a low estimate of $3.75, while EPS last year was $11.29. The consensus estimate for the next quarter is -$0.43, with high estimates of $2.55 and low estimates of -$2.1.

Analysts are recommending an EPS of between $22.07 and $20.13 for the fiscal current year, implying an average EPS of $21.23. EPS for the following year is $2.91, with 17 analysts recommending between $11.2 and -$4.88.

Revenue Estimates

In the current quarter, 13 analysts expect revenue to total $5.02B. It ranges from a high estimate of $5.29B to a low estimate of $4.81B. As of the current estimate, Moderna Inc.’s year-ago sales were $7.21B, an estimated decrease of -30.40% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $1.53B, a decrease of -74.80% less than the figure of -$30.40% in the same quarter last year. There is a high estimate of $3.1B for the next quarter, whereas the lowest estimate is $525M.

A total of 18 analysts have provided revenue estimates for MRNA’s current fiscal year. The highest revenue estimate was $19.47B, while the lowest revenue estimate was $18.4B, resulting in an average revenue estimate of $19.13B. In the same quarter a year ago, actual revenue was $18.47B, up 3.50% from the average estimate. Based on 18 analysts’ estimates, the company’s revenue will be $8.05B in the next fiscal year. The high estimate is $12.41B and the low estimate is $5.1B. The average revenue growth estimate for next year is down -57.90% from the average revenue estimate for this year.